{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:14:04Z","timestamp":1793783644813,"version":"4.6.1"},"reference-count":189,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genome Ed."],"abstract":"<jats:p>The liver is an essential organ of the body that performs several vital functions, including the metabolism of biomolecules, foreign substances, and toxins, and the production of plasma proteins, such as coagulation factors. There are hundreds of genetic disorders affecting liver functions and, for many of them, the only curative option is orthotopic liver transplantation, which nevertheless entails many risks and long-term complications. Some peculiar features of the liver, such as its large blood flow supply and the tolerogenic immune environment, make it an attractive target for <jats:italic>in vivo<\/jats:italic> gene therapy approaches. In recent years, several genome-editing tools mainly based on the clustered regularly interspaced short palindromic repeats associated protein 9 (CRISPR-Cas9) system have been successfully exploited in the context of liver-directed preclinical or clinical therapeutic applications. These include gene knock-out, knock-in, activation, interference, or base and prime editing approaches. Despite many achievements, important challenges still need to be addressed to broaden clinical applications, such as the optimization of the delivery methods, the improvement of the editing efficiency, and the risk of on-target or off-target unwanted effects and chromosomal rearrangements. In this review, we highlight the latest progress in the development of <jats:italic>in vivo<\/jats:italic> liver-targeted genome editing approaches for the treatment of genetic disorders. We describe the technological advancements that are currently under investigation, the challenges to overcome for clinical applicability, and the future perspectives of this technology.<\/jats:p>","DOI":"10.3389\/fgeed.2024.1458037","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T04:57:07Z","timestamp":1724389027000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["In vivo liver targeted genome editing as therapeutic approach: progresses and challenges"],"prefix":"10.3389","volume":"6","author":[{"given":"Chiara","family":"Simoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Barbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s F.","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Cantore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/nature24049","article-title":"RNA targeting with CRISPR\u2013Cas13","volume":"550","author":"Abudayyeh","year":"2017","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000578","article-title":"Emerging and potential use of CRISPR in human liver disease","author":"Adlat","year":"2023","journal-title":"Hepatology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.cell.2016.09.006","article-title":"Inheritable silencing of endogenous genes by hit-and-run targeted epigenetic editing","volume":"167","author":"Amabile","year":"2016","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-02078-y","article-title":"Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo","author":"An","year":"2024","journal-title":"Nat. Biotechnol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41587-021-01133-w","article-title":"Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing","volume":"40","author":"Anzalone","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/protein\/gzu028","article-title":"Nature\u2019s recipe for splitting inteins","volume":"27","author":"Aranko","year":"2014","journal-title":"Protein Eng. Des. Sel."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/bioinformatics\/btu048","article-title":"Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases","volume":"30","author":"Bae","year":"2014","journal-title":"Bioinformatics"},{"key":"B10","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","article-title":"Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins","volume":"185","author":"Banskota","year":"2022","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41434-020-00218-6","article-title":"Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor","volume":"30","author":"Barbon","year":"2023","journal-title":"Gene Ther."},{"key":"B12","article-title":"Long-term efficacy, safety, and extrahepatic benefit of liver-directed lentiviral gene therapy in a methylmalonic acidemia mouse model","author":"Barbon","year":"2024"},{"key":"B13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/jimd.12709","article-title":"Liver\u2010directed gene therapy for inherited metabolic diseases","volume":"47","author":"Baruteau","year":"2024","journal-title":"J. Inherit. Metab. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature13864","article-title":"Promoterless gene targeting without nucleases ameliorates haemophilia B in mice","volume":"517","author":"Barzel","year":"2015","journal-title":"Nature"},{"key":"B15","unstructured":"Beam therapeutics announces first patient dosed in the phase 1\/2 study of BEAM-302 in alpha-1 antitrypsin deficiency (AATD)2024"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1016\/j.ymthe.2023.03.024","article-title":"CRISPR-Cas-mediated transcriptional modulation: the therapeutic promises of CRISPRa and CRISPRi","volume":"31","author":"Bendixen","year":"2023","journal-title":"Mol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"5660","DOI":"10.1021\/acsnano.1c10631","article-title":"Robust, durable gene activation in vivo via mRNA-encoded activators","volume":"16","author":"Beyersdorf","year":"2022","journal-title":"ACS Nano"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s40265-022-01788-y","article-title":"Valoctocogene Roxaparvovec: first approval","volume":"82","author":"Blair","year":"2022","journal-title":"Drugs"},{"key":"B19","doi-asserted-by":"publisher","first-page":"eabl9238","DOI":"10.1126\/scitranslmed.abl9238","article-title":"In vivo prime editing of a metabolic liver disease in mice","volume":"14","author":"B\u00f6ck","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41573-019-0036-1","article-title":"Lysosomes as a therapeutic target","volume":"18","author":"Bonam","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1038\/s41467-023-39246-2","article-title":"Rapid and definitive treatment of phenylketonuria in variant-humanized mice with corrective editing","volume":"14","author":"Brooks","year":"2023","journal-title":"Nat. Commun."},{"key":"B22","doi-asserted-by":"publisher","first-page":"100253","DOI":"10.1016\/j.xhgg.2023.100253","article-title":"A base editing strategy using mRNA-LNPs for in vivo correction of the most frequent phenylketonuria variant","volume":"5","author":"Brooks","year":"2024","journal-title":"HGG Adv."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1140997","DOI":"10.3389\/fmmed.2023.1140997","article-title":"Gene transfer and genome editing for familial hypercholesterolemia","volume":"3","author":"Canepari","year":"2023","journal-title":"Front. Mol. Med."},{"key":"B24","article-title":"Lentiviral gene therapy to the liver for homozygous familial hypercholesterolemia (FH): assessing the best vector design","author":"Canepari","year":"2024"},{"key":"B25","doi-asserted-by":"publisher","first-page":"277ra28","DOI":"10.1126\/scitranslmed.aaa1405","article-title":"Liver-directed lentiviral gene therapy in a dog model of hemophilia B","volume":"7","author":"Cantore","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s41586-024-07087-8","article-title":"Durable and efficient gene silencing in vivo by hit-and-run epigenome editing","volume":"627","author":"Cappelluti","year":"2024","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nbt.4066","article-title":"A highly specific SpCas9 variant is identified by in vivo screening in yeast","volume":"36","author":"Casini","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1161\/ATVBAHA.117.309881","article-title":"In vivo base editing of PCSK9 (proprotein convertase subtilisin\/kexin type 9) as a therapeutic alternative to genome editing","volume":"37","author":"Chadwick","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/hep.31570","article-title":"Promoterless, nuclease-free genome editing confers a growth advantage for corrected hepatocytes in mice with methylmalonic acidemia","volume":"73","author":"Chandler","year":"2021","journal-title":"Hepatology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"16838","DOI":"10.1038\/s41598-019-53198-y","article-title":"Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII","volume":"9","author":"Chen","year":"2019","journal-title":"Sci. Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"102138","DOI":"10.1016\/j.omtn.2024.102138","article-title":"Recent advances in CRISPR-Cas9-based genome insertion technologies","volume":"35","author":"Chen","year":"","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B33","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.kint.2023.11.029","article-title":"In vivo base editing rescues primary hyperoxaluria type 1 in rats","volume":"105","author":"Chen","year":"","journal-title":"Kidney Int."},{"key":"B34","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1534\/genetics.110.120717","article-title":"Targeting DNA double-strand breaks with TAL effector nucleases","volume":"186","author":"Christian","year":"2010","journal-title":"Genetics"},{"key":"B35","unstructured":"Study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of NTLA-2001 in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) and patients with transthyretin amyloidosis-related cardiomyopathy (ATTR-CM)2023"},{"key":"B36","unstructured":"Gene therapy with hLB-001 in pediatric patients with severe methylmalonic acidemia (SUNRISE)"},{"key":"B37","unstructured":"MAGNITUDE: a phase 3 study of NTLA-2001 in participants with transthyretin amyloidosis with cardiomyopathy (ATTR-CM)"},{"key":"B38","unstructured":"NTLA-2002 in adults with hereditary angioedema (HAE) (NTLA-2002)"},{"key":"B39","unstructured":"A study of VERVE-101 in patients with familial hypercholesterolemia and cardiovascular disease"},{"key":"B40","unstructured":"A study of VERVE-102 in patients with familial hypercholesterolemia or premature coronary artery disease"},{"key":"B41","unstructured":"A study to evaluate the safety and efficacy of BEAM-302 in adult patients with alpha-1 antitrypsin deficiency (AATD)"},{"key":"B42","doi-asserted-by":"crossref","unstructured":"CRISPR therapeutics provides business update and reports fourth quarter and full year 2023 financial results2023","DOI":"10.1016\/j.fopow.2023.02.013"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1038\/mt.2008.72","article-title":"Gene delivery to the juvenile mouse liver using AAV2\/8 vectors","volume":"16","author":"Cunningham","year":"2008","journal-title":"Mol. Ther."},{"key":"B44","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41587-023-01758-z","article-title":"Efficient prime editing in mouse brain, liver and heart with dual AAVs","volume":"42","author":"Davis","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/s41551-022-00911-4","article-title":"Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors","volume":"6","author":"Davis","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e128863","DOI":"10.1172\/jci.insight.128863","article-title":"Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases","volume":"4","author":"De Caneva","year":"2019","journal-title":"JCI Insight"},{"key":"B47","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1161\/CIRCRESAHA.115.304351","article-title":"Permanent alteration of PCSK9 with in vivo CRISPR-cas9 genome editing","volume":"115","author":"Ding","year":"2014","journal-title":"Circ. Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41587-020-0414-6","article-title":"Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors","volume":"38","author":"Doman","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"10524","DOI":"10.1074\/jbc.TM118.000372","article-title":"Homologous recombination and the repair of DNA double-strand breaks","volume":"293","author":"Douglass Wright","year":"2018","journal-title":"J. Biol. Chem."},{"key":"B50","doi-asserted-by":"publisher","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"J. Virol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"101619","DOI":"10.1016\/j.xcrm.2024.101619","article-title":"Safe and effective liver-directed AAV-mediated homology-independent targeted integration in mouse models of inherited diseases","volume":"5","author":"Esposito","year":"2024","journal-title":"Cell Rep. Med."},{"key":"B52","unstructured":"FDA approves first gene therapies to treat patients with sickle cell disease2023"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"key":"B54","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41587-023-01915-4","article-title":"Genotoxic effects of base and prime editing in human hematopoietic stem cells","volume":"42","author":"Fiumara","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1089\/crispr.2021.0080","article-title":"Genomic and transcriptomic analyses of prime editing guide RNA\u2013independent off-target effects by prime editors","volume":"5","author":"Gao","year":"2022","journal-title":"CRISPR J."},{"key":"B57","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u22c5T to G\u22c5C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41592-021-01207-2","article-title":"Transgenic mice for in vivo epigenome editing with CRISPR-based systems","volume":"18","author":"Gemberling","year":"2021","journal-title":"Nat. Methods"},{"key":"B59","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41586-019-1161-z","article-title":"Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors","volume":"569","author":"Gr\u00fcnewald","year":"2019","journal-title":"Nature"},{"key":"B61","doi-asserted-by":"publisher","first-page":"102050","DOI":"10.1016\/j.omtn.2023.102050","article-title":"In vivo genome editing using 244-cis LNPs and low-dose AAV achieves therapeutic threshold in hemophilia A mice","volume":"34","author":"Han","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B62","doi-asserted-by":"publisher","first-page":"7275","DOI":"10.1038\/s41467-022-34898-y","article-title":"Low-dose AAV-CRISPR-mediated liver-specific knock-in restored hemostasis in neonatal hemophilia B mice with subtle antibody response","volume":"13","author":"He","year":"2022","journal-title":"Nat. Commun."},{"key":"B63","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40265-023-01845-0","article-title":"Etranacogene Dezaparvovec: first approval","volume":"83","author":"Heo","year":"2023","journal-title":"Drugs"},{"key":"B64","unstructured":"Intellia presents new interim data from the ongoing phase 1 study of NTLA-2001 at the 4th international ATTR amyloidosis meeting2023"},{"key":"B65","unstructured":"Intellia therapeutics announces first quarter 2024 financial results and highlights recent company progress2024"},{"key":"B66","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41551-021-00788-9","article-title":"Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases","volume":"6","author":"Jang","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e172614","DOI":"10.1172\/jci.insight.172614","article-title":"Synergism of dual AAV gene therapy and rapamycin rescues GSDIII phenotype in muscle and liver","volume":"9","author":"Jauze","year":"2024","journal-title":"JCI Insight"},{"key":"B68","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41587-021-01026-y","article-title":"Deletion and replacement of long genomic sequences using prime editing","volume":"40","author":"Jiang","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Sci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"16998","DOI":"10.1073\/pnas.1101874108","article-title":"Protein delivery using engineered virus-like particles","volume":"108","author":"Kaczmarczyk","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol. Ther."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.3390\/v15122395","article-title":"Gene-editing and RNA interference in treating hepatitis B: a review","volume":"15","author":"Kasianchuk","year":"2023","journal-title":"Viruses"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1038\/s41467-023-37465-1","article-title":"GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy","volume":"14","author":"Kasiewicz","year":"2023","journal-title":"Nat. Commun."},{"key":"B74","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41592-019-0323-0","article-title":"In vivo RNA editing of point mutations via RNA-guided adenosine deaminases","volume":"16","author":"Katrekar","year":"2019","journal-title":"Nat. Methods"},{"key":"B75","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/s41587-021-01171-4","article-title":"Efficient in vitro and in vivo RNA editing via recruitment of endogenous ADARs using circular guide RNAs","volume":"40","author":"Katrekar","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-nanoparticle-based delivery of CRISPR\/Cas9 genome-editing components","volume":"19","author":"Kazemian","year":"2022","journal-title":"Mol. Pharm."},{"key":"B77","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.tig.2017.08.008","article-title":"Gene therapy with the sleeping beauty transposon system","volume":"33","author":"Kebriaei","year":"2017","journal-title":"Trends Genet."},{"key":"B78","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.3390\/jcm12175586","article-title":"New developments and challenges in liver transplantation","volume":"12","author":"Khalil","year":"2023","journal-title":"J. Clin. Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.tig.2022.12.001","article-title":"Clinical progress in genome-editing technology and in vivo delivery techniques","volume":"39","author":"Khirallah","year":"2023","journal-title":"Trends Genet."},{"key":"B80","doi-asserted-by":"publisher","first-page":"10576","DOI":"10.1093\/nar\/gkaa764","article-title":"Unbiased investigation of specificities of prime editing systems in human cells","volume":"48","author":"Kim","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.ymthe.2024.03.006","article-title":"On- and off-target effects of paired CRISPR-Cas nickase in primary human cells","volume":"32","author":"Klermund","year":"2024","journal-title":"Mol. Ther."},{"key":"B82","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41586-019-1323-z","article-title":"Transposon-encoded CRISPR\u2013Cas systems direct RNA-guided DNA integration","volume":"571","author":"Klompe","year":"2019","journal-title":"Nature"},{"key":"B83","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.3390\/v13081528","article-title":"Lentiviral vectors for T cell engineering: clinical applications, bioprocessing and future perspectives","volume":"13","author":"Labb\u00e9","year":"2021","journal-title":"Viruses"},{"key":"B85","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41587-023-01748-1","article-title":"Targeted DNA integration in human cells without double-strand breaks using CRISPR-associated transposases","volume":"42","author":"Lampe","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","article-title":"Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine","volume":"4","author":"Lee","year":"2017","journal-title":"Genes Dis."},{"key":"B87","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.omtn.2023.03.008","article-title":"In vivo genome editing for hemophilia B therapy by the combination of rebalancing and therapeutic gene knockin using a viral and non-viral vector","volume":"32","author":"Lee","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B88","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41588-021-00838-7","article-title":"Chromothripsis as an on-target consequence of CRISPR\u2013Cas9 genome editing","volume":"53","author":"Leibowitz","year":"2021","journal-title":"Nat. Genet."},{"key":"B89","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41551-019-0501-5","article-title":"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses","volume":"4","author":"Levy","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.ymthe.2020.04.017","article-title":"AAV-CRISPR gene editing is negated by pre-existing immunity to Cas9","volume":"28","author":"Li","year":"2020","journal-title":"Mol. Ther."},{"key":"B91","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature10177","article-title":"In vivo genome editing restores haemostasis in a mouse model of haemophilia","volume":"475","author":"Li","year":"2011","journal-title":"Nature"},{"key":"B92","doi-asserted-by":"publisher","first-page":"785698","DOI":"10.3389\/fgeed.2022.785698","article-title":"Promoterless gene targeting approach combined to CRISPR\/Cas9 efficiently corrects hemophilia B phenotype in neonatal mice","volume":"4","author":"Lisjak","year":"2022","journal-title":"Front. Genome"},{"key":"B93","doi-asserted-by":"publisher","first-page":"101103","DOI":"10.1016\/j.omtm.2023.08.022","article-title":"Lethality rescue and long-term amelioration of a citrullinemia type I mouse model by neonatal gene-targeting combined to SaCRISPR-Cas9","volume":"31","author":"Lisjak","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/s41467-021-22295-w","article-title":"Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/nbt1353","article-title":"Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery","volume":"25","author":"Lombardo","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa2309149","article-title":"CRISPR-Cas9 in vivo gene editing of KLKB1 for hereditary angioedema","volume":"390","author":"Longhurst","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3390\/life10120366","article-title":"Virus-like particle mediated CRISPR\/Cas9 delivery for efficient and safe genome editing","volume":"10","author":"Lyu","year":"2020","journal-title":"Life"},{"key":"B98","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41579-019-0299-x","article-title":"Evolutionary classification of CRISPR\u2013Cas systems: a burst of class 2 and derived variants","volume":"18","author":"Makarova","year":"2020","journal-title":"Nat. Rev. Microbiol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41467-018-07845-z","article-title":"Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins","volume":"10","author":"Mangeot","year":"2019","journal-title":"Nat. Commun."},{"key":"B100","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nature21022","article-title":"Reversible methylation of m6Am in the 5\u2032 cap controls mRNA stability","volume":"541","author":"Mauer","year":"2017","journal-title":"Nature"},{"key":"B101","doi-asserted-by":"publisher","first-page":"eaav7325","DOI":"10.1126\/scitranslmed.aav7325","article-title":"Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates","volume":"11","author":"Milani","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1038\/s41467-022-30102-3","article-title":"Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primates","volume":"13","author":"Milani","year":"2022","journal-title":"Nat. Commun."},{"key":"B103","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"key":"B104","doi-asserted-by":"publisher","first-page":"5560","DOI":"10.1038\/ncomms6560","article-title":"Microhomology-mediated end-joining-dependent integration of donor DNA in cells and animals using TALENs and CRISPR\/Cas9","volume":"5","author":"Nakade","year":"2014","journal-title":"Nat. Commun."},{"key":"B105","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"key":"B106","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41587-022-01533-6","article-title":"Evolution of an adenine base editor into a small, efficient cytosine base editor with low off-target activity","volume":"41","author":"Neugebauer","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ymthe.2018.10.018","article-title":"ZFN-mediated in vivo genome editing corrects murine hurler syndrome","volume":"27","author":"Ou","year":"2019","journal-title":"Mol. Ther."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene Roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.ymthe.2022.01.040","article-title":"Evaluation of cytosine base editing and adenine base editing as a potential treatment for alpha-1 antitrypsin deficiency","volume":"30","author":"Packer","year":"2022","journal-title":"Mol. Ther."},{"key":"B110","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.omtm.2022.08.004","article-title":"Full-length ATP7B reconstituted through protein trans-splicing corrects Wilson disease in mice","volume":"26","author":"Padula","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B111","doi-asserted-by":"publisher","first-page":"e171281","DOI":"10.1172\/jci.insight.171281","article-title":"Genome editing without nucleases confers proliferative advantage to edited hepatocytes and corrects Wilson disease","volume":"8","author":"Padula","year":"2023","journal-title":"JCI Insight"},{"key":"B112","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1016\/j.ymthe.2021.03.018","article-title":"ZFN-mediated in vivo gene editing in hepatocytes leads to supraphysiologic a-Gal A activity and effective substrate reduction in Fabry mice","volume":"29","author":"Pagant","year":"2021","journal-title":"Mol. Ther."},{"key":"B113","doi-asserted-by":"publisher","first-page":"7071","DOI":"10.1038\/s41467-021-27183-x","article-title":"Find and cut-and-transfer (FiCAT) mammalian genome engineering","volume":"12","author":"Pallar\u00e8s-Masmitj\u00e0","year":"2021","journal-title":"Nat. Commun."},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-024-01227-1","article-title":"Efficient site-specific integration of large genes in mammalian cells via continuously evolved recombinases and prime editing","author":"Pandey","year":"2024","journal-title":"Nat. Biomed. Eng"},{"key":"B115","doi-asserted-by":"publisher","first-page":"10512","DOI":"10.1074\/jbc.TM117.000374","article-title":"Nonhomologous DNA end-joining for repair of DNA double-strand breaks","volume":"293","author":"Pannunzio","year":"2018","journal-title":"J. Biol. Chem."},{"key":"B116","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"B117","article-title":"Demonstration of nuclease-free genome editing (GeneRideTM) in pediatric patients with methylmalonic acidemia","author":"Payton","year":"2024"},{"key":"B118","unstructured":"U.S. FDA approves pfizer\u2019s BEQVEZTM (fidanacogene elaparvovec-dzkt), a one-time gene therapy for adults with hemophilia B2024"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.15252\/emmm.201707601","article-title":"Promoterless gene targeting without nucleases rescues lethality of a Crigler\u2010Najjar syndrome mouse model","volume":"9","author":"Porro","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"B120","doi-asserted-by":"publisher","first-page":"e3002071","DOI":"10.1371\/journal.pbio.3002071","article-title":"In the business of base editors: evolution from bench to bedside","volume":"21","author":"Porto","year":"2023","journal-title":"PLoS Biol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41573-020-0084-6","article-title":"Base editing: advances and therapeutic opportunities","volume":"19","author":"Porto","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"B122","unstructured":"Prime medicine reports first quarter 2024 financial results and provides business updates2024"},{"key":"B123","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1016\/j.ymthe.2022.09.015","article-title":"AAV vectors: the Rubik\u2019s cube of human gene therapy","volume":"30","author":"Pupo","year":"2022","journal-title":"Mol. Ther."},{"key":"B124","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic in vivo delivery of gene editing agents","volume":"185","author":"Raguram","year":"2022","journal-title":"Cell"},{"key":"B125","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"B126","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.omtm.2019.12.004","article-title":"AAV-mediated CRISPR\/Cas9 gene editing in murine phenylketonuria","volume":"17","author":"Richards","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B127","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","article-title":"In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels","volume":"39","author":"Rothgangl","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"6064","DOI":"10.1073\/pnas.91.13.6064","article-title":"Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells","volume":"91","author":"Rouet","year":"1994","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B129","doi-asserted-by":"publisher","first-page":"5215","DOI":"10.1038\/s41467-022-32906-9","article-title":"In vivo adenine base editing reverts C282Y and improves iron metabolism in hemochromatosis mice","volume":"13","author":"Rovai","year":"2022","journal-title":"Nat. Commun."},{"key":"B130","doi-asserted-by":"publisher","first-page":"10536","DOI":"10.1074\/jbc.TM117.000375","article-title":"Repair of DNA double-strand breaks by mammalian alternative end-joining pathways","volume":"27","author":"Sallmyr","year":"2018","journal-title":"J. Biol. Chem."},{"key":"B131","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S0140-6736(23)01952-9","article-title":"A new age of precision gene therapy","volume":"403","author":"Schambach","year":"2024","journal-title":"Lancet"},{"key":"B132","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.stem.2019.02.019","article-title":"Precise gene editing preserves hematopoietic stem cell function following transient p53-mediated DNA damage response","volume":"24","author":"Schiroli","year":"2019","journal-title":"Cell Stem Cell"},{"key":"B133","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.1074\/jbc.RA117.000347","article-title":"Cas9-nickase\u2013mediated genome editing corrects hereditary tyrosinemia in rats","volume":"293","author":"Shao","year":"2018","journal-title":"J. Biol. Chem."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1182\/blood-2014-12-615492","article-title":"In vivo genome editing of the albumin locus as a platform for protein replacement therapy","volume":"126","author":"Sharma","year":"2015","journal-title":"Blood"},{"key":"B135","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/d41587-023-00016-6","article-title":"The world\u2019s first CRISPR therapy is approved: who will receive it?","volume":"42","author":"Sheridan","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune responses to viral gene therapy vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"B137","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.omtm.2018.06.006","article-title":"Prevalence of pre-existing antibodies to CRISPR-associated nuclease Cas9 in the USA population","volume":"10","author":"Simhadri","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B138","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41434-018-0003-1","article-title":"Targeted in vivo knock-in of human alpha-1-antitrypsin cDNA using adenoviral delivery of CRISPR\/Cas9","volume":"25","author":"Stephens","year":"2018","journal-title":"Gene Ther."},{"key":"B139","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev-biochem-080320-110356","article-title":"Repair of DNA double-strand breaks by the nonhomologous end joining pathway","volume":"90","author":"Stinson","year":"2021","journal-title":"Annu. Rev. Biochem."},{"key":"B140","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.str.2010.12.003","article-title":"Homing endonucleases: from microbial genetic invaders to reagents for targeted DNA modification","volume":"19","author":"Stoddard","year":"2011","journal-title":"Structure"},{"key":"B141","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.omtm.2020.11.014","article-title":"CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice","volume":"20","author":"Stone","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B142","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1126\/science.aax9181","article-title":"RNA-guided DNA insertion with CRISPR-associated transposases","volume":"365","author":"Strecker","year":"2019","journal-title":"Science"},{"key":"B143","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s43556-023-00120-8","article-title":"In vivo adenine base editing corrects newborn murine model of Hurler syndrome","volume":"4","author":"Su","year":"2023","journal-title":"Mol. Biomed."},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02171-w","article-title":"Genome engineering with Cas9 and AAV repair templates generates frequent concatemeric insertions of viral vectors","author":"Suchy","year":"2024","journal-title":"Nat. Biotechnol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nature20565","article-title":"In vivo genome editing via CRISPR\/Cas9 mediated homology-independent targeted integration","volume":"540","author":"Suzuki","year":"2016","journal-title":"Nature"},{"key":"B146","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41467-023-35886-6","article-title":"Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing","volume":"14","author":"Tao","year":"2023","journal-title":"Nat. Commun."},{"key":"B147","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1038\/s41467-022-31322-3","article-title":"Frequency and mechanisms of LINE-1 retrotransposon insertions at CRISPR\/Cas9 sites","volume":"13","author":"Tao","year":"2022","journal-title":"Nat. Commun."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1038\/s41467-018-04048-4","article-title":"RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors","volume":"9","author":"Thakore","year":"2018","journal-title":"Nat. Commun."},{"key":"B149","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s44321-023-00008-8","article-title":"Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1","volume":"16","author":"Torella","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"B150","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1038\/s41467-022-29550-8","article-title":"Therapeutic homology-independent targeted integration in retina and liver","volume":"13","author":"Tornabene","year":"2022","journal-title":"Nat. Commun."},{"key":"B189","doi-asserted-by":"publisher","first-page":"eaav4523","DOI":"10.1126\/scitranslmed.aav4523","article-title":"Intein-mediated protein trans-splicing expands adeno-associated virus transfer capacity in the retina","volume":"11","author":"Tornabene","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"B151","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41587-022-01574-x","article-title":"Precise cut-and-paste DNA insertion using engineered type V-K CRISPR-associated transposases","volume":"41","author":"Tou","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"B188","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/emmm.201302948","article-title":"Effective delivery of large genes to the retina by dual AAV vectors","volume":"6","author":"Trapani","year":"2014","journal-title":"EMBO Mol Med."},{"key":"B152","doi-asserted-by":"publisher","first-page":"R1147","DOI":"10.1016\/j.cub.2017.09.019","article-title":"The liver","volume":"27","author":"Trefts","year":"2017","journal-title":"Curr. Biol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nmeth.4278","article-title":"CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR\u2013Cas9 nuclease off-targets","volume":"14","author":"Tsai","year":"2017","journal-title":"Nat. Methods"},{"key":"B154","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nbt.3117","article-title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases","volume":"33","author":"Tsai","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/s41587-022-01240-2","article-title":"Fludarabine increases nuclease-free AAV- and CRISPR\/Cas9-mediated homologous recombination in mice","volume":"40","author":"Tsuji","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/s41467-022-28762-2","article-title":"A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders","volume":"13","author":"Tucci","year":"2022","journal-title":"Nat. Commun."},{"key":"B157","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.stem.2021.02.002","article-title":"Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq","volume":"28","author":"Turchiano","year":"2021","journal-title":"Cell Stem Cell"},{"key":"B158","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.3390\/ijms24054778","article-title":"Toward the development of epigenome editing-based therapeutics: potentials and challenges","volume":"24","author":"Ueda","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B159","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/s41591-018-0137-0","article-title":"A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells","volume":"24","author":"Vakulskas","year":"2018","journal-title":"Nat. Med."},{"key":"B161","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.tibtech.2022.12.022","article-title":"The genome editing revolution","volume":"41","author":"van der Oost","year":"2023","journal-title":"Trends Biotechnol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymgme.2022.06.011","article-title":"Growth advantage of corrected hepatocytes in a juvenile model of methylmalonic acidemia following liver directed adeno-associated viral mediated nuclease-free genome editing","volume":"137","author":"Venturoni","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"B163","unstructured":"Verve therapeutics announces pipeline progress and reports first quarter 2024 financial results"},{"key":"B164","unstructured":"Verve therapeutics announces updates on its PCSK9 program"},{"key":"B165","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41580-023-00697-6","article-title":"CRISPR technologies for genome, epigenome and transcriptome editing","volume":"25","author":"Villiger","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-018-0209-1","article-title":"Treatment of a metabolic liver disease by in vivo genome base editing in adult mice","volume":"24","author":"Villiger","year":"2018","journal-title":"Nat. Med."},{"key":"B167","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41434-021-00232-2","article-title":"Cas9-directed immune tolerance in humans\u2014a model to evaluate regulatory T cells in gene therapy?","volume":"28","author":"Wagner","year":"2021","journal-title":"Gene Ther."},{"key":"B168","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1089\/hum.2015.087","article-title":"Adenovirus-mediated somatic genome editing of Pten by CRISPR\/Cas9 in mouse liver in spite of Cas9-specific immune responses","volume":"26","author":"Wang","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"B169","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"","journal-title":"Nat. Rev. Drug Discov."},{"key":"B170","doi-asserted-by":"publisher","first-page":"eadd8643","DOI":"10.1126\/science.add8643","article-title":"CRISPR technology: a decade of genome editing is only the beginning","volume":"379","author":"Wang","year":"2023","journal-title":"Science"},{"key":"B171","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1089\/hum.2011.183","article-title":"Hepatic gene transfer in neonatal mice by adeno-associated virus serotype 8 vector","volume":"23","author":"Wang","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"B172","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1126\/sciadv.aax5701","article-title":"A mutation-independent CRISPR-Cas9-mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency","volume":"6","author":"Wang","year":"2020","journal-title":"Sci. Adv."},{"key":"B173","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood.2019000790","article-title":"CRISPR\/Cas9-mediated in vivo gene targeting corrects hemostasis in newborn and adult factor IX-knockout mice","volume":"133","author":"Wang","year":"","journal-title":"Blood"},{"key":"B174","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/mt.2009.122","article-title":"Integration-deficient lentiviral vectors: a slow coming of age","volume":"17","author":"Wanisch","year":"2009","journal-title":"Mol. Ther."},{"key":"B175","doi-asserted-by":"publisher","first-page":"658399","DOI":"10.3389\/fimmu.2021.658399","article-title":"Anti-AAV antibodies in AAV gene therapy: current challenges and possible solutions","volume":"12","author":"Weber","year":"2021","journal-title":"Front. Immunol."},{"key":"B176","doi-asserted-by":"publisher","first-page":"665184","DOI":"10.3389\/fmicb.2021.665184","article-title":"Inhibition of hepatitis B virus by AAV8-derived CRISPR\/SaCas9 expressed from liver-specific promoters","volume":"12","author":"Yan","year":"2021","journal-title":"Front. Microbiol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ebiom.2017.05.015","article-title":"CRISPR\/Cas9 \u2013 mediated precise targeted integration in vivo using a double cut donor with short homology arms","volume":"20","author":"Yao","year":"2017","journal-title":"EBioMedicine"},{"key":"B178","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41587-022-01527-4","article-title":"Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases","volume":"41","author":"Yarnall","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"B179","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s41587-021-01180-3","article-title":"Engineered circular ADAR-recruiting RNAs increase the efficiency and fidelity of RNA editing in vitro and in vivo","volume":"40","author":"Yi","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"B180","doi-asserted-by":"publisher","first-page":"53","DOI":"10.34763\/jmotherandchild.20202402si.2004.000009","article-title":"Gene therapy for inherited metabolic diseases","volume":"24","author":"Yilmaz","year":"2020","journal-title":"J. Mother Child."},{"key":"B181","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/nbt.4005","article-title":"Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing","volume":"35","author":"Yin","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"B182","doi-asserted-by":"publisher","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","article-title":"Hepatitis B virus infection","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B183","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1097\/HEP.0000000000000700","article-title":"Base editing of the mutated TERT promoter inhibits liver tumor growth","volume":"79","author":"Zhao","year":"2024","journal-title":"Hepatology"},{"key":"B184","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.ymthe.2022.01.005","article-title":"A flexible split prime editor using truncated reverse transcriptase improves dual-AAV delivery in mouse liver","volume":"30","author":"Zheng","year":"2022","journal-title":"Mol. Ther."},{"key":"B185","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1038\/s41467-023-39137-6","article-title":"Template-jumping prime editing enables large insertion and exon rewriting in vivo","volume":"14","author":"Zheng","year":"2023","journal-title":"Nat. Commun."},{"key":"B186","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nbt0997-871","article-title":"Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo","volume":"15","author":"Zufferey","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"B187","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1126\/science.aav9973","article-title":"Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos","volume":"364","author":"Zuo","year":"2019","journal-title":"Science"}],"container-title":["Frontiers in Genome Editing"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgeed.2024.1458037\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T15:37:31Z","timestamp":1724427451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgeed.2024.1458037\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":189,"alternative-id":["10.3389\/fgeed.2024.1458037"],"URL":"https:\/\/doi.org\/10.3389\/fgeed.2024.1458037","relation":{},"ISSN":["2673-3439"],"issn-type":[{"value":"2673-3439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,23]]},"article-number":"1458037"}}